About Asako

Asako assists life sciences and pharmaceutical companies with developing worldwide patent strategies and maintaining robust patent portfolios. She has extensive experience in drafting, prosecuting and managing patent applications, with a particular emphasis on small-molecule pharmaceuticals that are in various stages of development.

View full bio

Experience

Blue Owl Capital Invests up to $262.5 Million in ITM Isotope Technologies Munich SE

Blue Owl Capital Invests up to $262.5 Million in ITM Isotope Technologies Munich SE

May 27, 2025

Cooley advised Blue Owl Capital (NYSE: OWL), an asset manager redefining alternatives, on an up to $262.5 million term loan facility for ITM Isotope Technologies Munich SE, a radiopharmaceutical biotech company dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors.

Read more

Related contacts

Michael Tollini
Partner, Washington, DC
Addison Pierce
Partner, Chicago
Dr. Jon Cousin
Partner, Washington, DC
Geoffrey Spolyar
Partner, Boston
Xander Lee
Partner, Santa Monica
Phil Mitchell
Partner, New York
Steve Flores
Partner, Chicago
Susan Piascik Christoff
Special Counsel, Washington, DC
Randy Sabett
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Wyatt Kernell
Associate, Colorado
Matt Kong
Associate, San Francisco
Dr. Asako Kubota
Associate, Washington, DC
Allison Kutner
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Charles A. Watkins II
Associate, Santa Monica
Jennifer Fitzpatrick
Paralegal Specialist, Washington, DC
Margie Murphy
Paralegal Specialist, New York
Larry Teague
Patent Agent, Seattle

Related Practices & Industries

Debt Finance
Patent Counseling and Prosecution
Life Sciences
Tax
Life Sciences and Healthcare Regulatory
Healthcare
Biotechnology
Trademark, Copyright and Advertising
Cyber/Data/Privacy
CFIUS
Compensation and Benefits

Manage the global patent portfolio of Usher III Initiative

Manage the global patent portfolio of Usher III Initiative

June 23, 2016

Cooley manages the global patent portfolio of Usher III Initiative, Inc., a research consortium of leading retinal and cochlear specialists established to develop treatments for Usher Syndrome Type III.  Usher Syndrome is a genetic disorder that causes progressive hearing and vision loss and affects less than 0.01% of the population worldwide. Cooley’s work has resulted in the issuance of US and foreign patents covering small-molecule therapeutics showing promise as drugs useful for treating Usher Syndrome Type III.

Related contacts

Dr. Matthew Langer
Senior Counsel , New York
Dr. Asako Kubota
Associate, Washington, DC

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Intellectual Property
Patent Counseling and Prosecution
Patent Counseling and Prosecution – Life Sciences
Life Sciences

Admissions and credentials

District of Columbia

Registered to practice before the United States Patent and Trademark Office (USPTO)